Q1 2019 13F Holders as of 31 Mar 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
22,967,654
-
Share change
-
+2,091,200
-
Total reported value
-
$2,569,063,573
-
Put/Call ratio
-
186%
-
Price per share
-
$111.86
-
Number of holders
-
200
-
Value change
-
+$254,710,659
-
Number of buys
-
126
-
Number of sells
-
75
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q1 2019
As of 31 Mar 2019,
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) was held by
200 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,967,654 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, FIRST TRUST ADVISORS LP, JPMORGAN CHASE & CO, BB BIOTECH AG, CITADEL ADVISORS LLC, Senvest Management, LLC, and Point72 Asset Management, L.P..
This page lists
200
institutional shareholders reporting positions in this security
for the Q1 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.